Drugs / Measles, mumps, and rubella virus vaccine, live
Measles, mumps, and rubella virus vaccine, live
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT00257127 | Feb → Aug 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03673462 Background | Sep 2018 → Mar 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella virus vaccine, live | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257127 ↗ |
| Known as | M-M-R II | “M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age” NCT03673462 ↗ |
| Known as | Measles, Mumps, and Rubella Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673462 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella virus vaccine, live” NCT00257127 ↗ |
| Route | Subcutaneous | “Route of administration: Subcutaneous” NCT03673462 ↗ |